How to cite item

Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer

   
@article{JTD29198,
	author = {Vincent K. Lam and Jianjun Zhang},
	title = {Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer},
	journal = {Journal of Thoracic Disease},
	volume = {11},
	number = {6},
	year = {2019},
	keywords = {},
	abstract = {Tumor mutation burden (TMB) measures the number of somatic coding alterations in a tumor. Increased presence of these alterations contributes to immunogenicity through the generation of neoantigens targeted by T cell responses. Accordingly, a higher TMB is associated with favorable response rate and survival across multiple cancer types (1). TMB is independent of PD-L1 and is emerging as a promising immunotherapy biomarker. In non-small cell lung cancer (NSCLC), multiple studies have affirmed the utility of TMB as a marker for response to immune checkpoint inhibitors (ICI) (2-5). For example, advanced NSCLC patients with high TMB (≥10 mutations per Mb) treated with front-line combination ICI therapy had improved progression-free survival (PFS) compared to standard chemotherapy (HR 0.58, P},
	issn = {2077-6624},	url = {https://jtd.amegroups.org/article/view/29198}
}